NEW YORK (GenomeWeb) – Biocept said today that it has signed a provider agreement with Alliance Global to market and distribute its Target Selector liquid biopsy tests in the United Arab Emirates, as well as select countries in the Middle East, North and Sub-Saharan Africa, and Southeast Asia region.

Under the agreement, Biocept will perform all diagnostic testing services in its San Diego CLIA-certified laboratory. Alliance Global will be responsible for sales, marketing, distribution, and reimbursement. Additional terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.